1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025: Prospects for siRNAs, shRNAs and ddRNAi Approaches

Report Details
RNAi therapies – new study showing you trends, R&D progress, and predicted revenues
When will RNAi therapies reach the market? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 180-page report provides 95 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Joseph Payne, CEO, Arcturus Therapeutics
- J. Michael French, President and CEO, Marina Biotech
- Dr. Ana I. Jiménez, COO and R&D Director, Sylentis

See revenue forecasts for the most promising products in development
How will leading RNAi therapies perform to 2025 at world level? Our study forecasts sales of 11 products, including:
- ALN-TTR02 (patisiran)
- Vigil immunotherapy
- ALN-TTRsc (revusiran)
- ARC-520
- Atu027
- PF-655
- QPI-1002
- RXI-109
- siG12D-LODER
- SPC3649 (miravirsen)
- SYL040012

Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 4 regional markets plus the Rest of the World to 2025:
- US
- EU5
- Asia-Pacific
- Latin America
- Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the US, in particular, will achieve high revenue growth to 2025. Developments worldwide in biotechnology infrastructure and RNAi therapy development will influence the market.

Leading companies and potential for market growth
Overall world revenue for RNAi therapies will reach $391m in 2018, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and high unmet medical needs in many markets will increase sales to 2025.

Our work shows you what organisations hold greatest potential. See visiongain’s analysis of 11 leading companies, including these:
- Alnylam Pharmaceuticals
- Arrowhead Research
- Benitec Biopharma
- Gradalis Incorporated
- Quark Pharmaceuticals
- Roche Innovation Center Copenhagen (formerly Santaris Pharma)
- RXi Pharmaceuticals
- Silence Therapeutics
- Silenseed
- Sylentis
- Tekmira Pharmaceuticals.

A company profile gives you the following information where available:
- Historical revenues from 2010 to 2014
- Discussion of a company’s activities and outlook
- Recent financial results
- Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas and technologies:
- Small interfering RNA (siRNA) therapies
- Sh

Table Of Contents

RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025: Prospects for siRNAs, shRNAs and ddRNAi Approaches
Table of Contents
1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report

3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases - Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases - Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders - Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease - Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)

4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025

5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025

6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company's Market Position
6.2.3.2 Arrowhead Acquires Novartis' RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia's CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics' RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest

7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline

8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry's Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors

9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics' RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech's RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics
9.3 Interview with Dr. Ana I. Jimenez, COO and RandD Director, Sylentis, Madrid, Spain
9.3.1 Sylentis' RNAi Therapies Pipeline
9.3.2 Barriers to Market Entry
9.3.3 Opportunities for RNAi Developers
9.3.4 Interest from Big Pharma and Investors
9.3.5 Therapeutic Areas and Targets for RNAi Developers
9.3.6 The Intellectual Property Landscape of RNAi Therapies
9.3.7 Other Trends and Developments in RNAi Therapeutics

10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?

11. Glossary

List of Tables
Table 1.1 Leading Regional RNAi Therapies Market Forecast 2015 ($m, AGR%)
Table 2.1 Advantages and Disadvantages of Chemically-Modified Synthetic siRNAs, 2015
Table 2.2 Advantages of ddRNAi over siRNAs, 2015
Table 2.3 Clinical Trial Phases
Table 2.4 Currency Exchange Rates, 2014
Table 3.1 RNAi Pipeline Therapies by Therapeutic Area, 2015
Table 4.1 World RNAi Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 5.1 World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 5.2 Market Shares (%) of Leading Regional RNAi Therapies Markets, 2020 and 2025
Table 5.3 US RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.4 EU5 RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Asia-Pacific RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Latin American RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Rest of the World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.1 Alnylam Pharmaceuticals: RNAi Pipeline for Genetic Medicine, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.2 Alnylam Pharmaceuticals: RNAi Pipeline for Cardio-Metabolic Disease, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.3 Alnylam Pharmaceuticals: RNAi Pipeline for Hepatic Infectious Disease, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.4 Alnylam Pharmaceuticals: Revenue from Collaborators ($m), 2012-2014
Table 6.5 Alnylam Pharmaceuticals: Revenue ($m), Revenue Share (%) from Collaborators, 2014
Table 6.6 Alnylam: Revenue ($m), AGR(%), 2010-2014
Table 6.7 Arrowhead Research: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.8 Arrowhead Research: Revenue ($m), AGR(%), 2010-2014
Table 6.9 Benitec Biopharma: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.10 Benitec Biopharma: Revenue ($m), AGR(%), 2010-2014
Table 6.11 Gradalis: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.12 Quark Pharmaceuticals: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.13 Roche: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.14 RXi Pharmaceuticals: Revenue ($m), AGR(%), 2010-2014
Table 6.15 Silence Therapeutics: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.16 Silence Therapeutics: Revenue ($m), AGR(%), 2010-2014
Table 6.17 Silenseed: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.18 Sylentis: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.19 Tekmira: RNAi Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 6.20 Tekmira: Revenue from Collaborators ($m), 2012-2014
Table 6.21 Tekmira: Revenue ($m), Revenue Share (%) from Collaborators, 2014
Table 6.22 Tekmira: Revenue ($m), AGR(%), 2010-2014
Table 7.1 RNAi Pipeline Therapies by Phase, 2015
Table 7.2 RNAi Therapies Pipeline: Phase 3 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.3 Alnylam/Genzyme: ALN-TTR02 (patisiran) Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.4 Alnylam/Genzyme: ALN-TTRsc (revusiran) Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.5 Gradalis: Vigil Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.6 RNAi Therapies Pipeline: Phase 2 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.7 Arrowhead: ARC-520 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.8 Silence Therapeutics: Atu027 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.9 Quark: PF-655 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.10 Quark: QPI-1002 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.11 RXi: RXI-109 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.12 Silenseed: siG12D-LODER Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.13 Roche: SPC3649 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.14 Sylentis: SYL040012 Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.15 RNAi Therapies Pipeline: Phase 1 Drugs, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 7.16 RNAi Therapies Pipeline: Drugs in Preclinical Development, 2015 (Company, Name, Target, Indication, Phase of Development)
Table 8.1 Leading Contract Manufacturing Organisations Developing Oligonucleotide APIs, 2015 (Company, Country, Link)
Table 8.2 Advantages of Local Delivery Over Systemic Delivery, 2015
Table 8.3 Leading Companies Developing RNAi Delivery Systems and Technologies, 2015 (Company, Technology, Link)
Table 8.4 Leading Companies Developing Antisense Drugs, 2015 (Company, Lead Candidate, Indication, Phase of Development)
Table 8.5 Leading Companies Developing Aptamer Drugs, 2015 (Company, Lead Candidate, Indication, Phase of Development)
Table 10.1 RNAi Therapies Late-Stage Pipeline, 2015 (Company, Name, Target, Indication, Phase of Development)

List of Figures
Figure 1.1 Number of Unique RNAi Pipeline Products by Company, 2015
Figure 2.1 Structure of RNA and DNA, 2015
Figure 2.2 RNA Interference in Protein Synthesis
Figure 2.3 Summary of the Molecular Process of RNA Interference
Figure 3.1 RNAi Pipeline Therapies by Therapeutic Area, 2015
Figure 4.1 World RNAi Therapies Market Forecast: Revenue ($m), AGR (%), 2014-2025
Figure 4.2 World RNAi Therapies Market: Drivers and Restraints, 2015-2025
Figure 5.1 World RNAi Therapies Market Forecast: Revenues ($m) by Region, 2014-2025
Figure 5.2 World RNAi Therapies Market: Market Shares (%) by Region, 2020
Figure 5.3 World RNAi Therapies Market: Market Shares (%) by Region, 2025
Figure 5.4 US RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.5 EU5 RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.6 Asia-Pacific RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.7 Latin American RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.8 Rest of the World RNAi Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.1 Alnylam Pharmaceuticals: Revenue Share (%) from Collaborators, 2014
Figure 6.2 Alnylam: Revenue ($m), AGR(%), 2010-2014
Figure 6.3 Arrowhead Research: Revenue ($m), AGR(%), 2010-2014
Figure 6.4 Benitec Biopharma: Revenue ($m), AGR(%), 2010-2014
Figure 6.5 RXi Pharmaceuticals: Revenue ($m), AGR(%), 2010-2014
Figure 6.6 Silence Therapeutics: Revenue ($m), AGR(%), 2010-2014
Figure 6.7 Tekmira: Revenue Share (%) from Collaborators, 2014
Figure 6.8 Tekmira: Revenue ($m), AGR(%), 2010-2014
Figure 7.1 RNAi Pipeline Therapies by Phase, 2015
Figure 7.2 Alnylam/Genzyme: ALN-TTR02 (patisiran) Revenue ($m), AGR (%), 2014-2025
Figure 7.3 Alnylam/Genzyme: ALN-TTRsc (revusiran) Revenue ($m), AGR (%), 2014-2025
Figure 7.4 Gradalis: Vigil Revenue ($m), AGR (%), 2014-2025
Figure 7.5 Arrowhead: ARC-520 Revenue ($m), AGR (%), 2014-2025
Figure 7.6 Silence Therapeutics: Atu027 Revenue ($m), AGR (%), 2014-2025
Figure 7.7 Quark: PF-655 Revenue ($m), AGR (%), 2014-2025
Figure 7.8 Quark: QPI-1002 Revenue ($m), AGR (%), 2014-2025
Figure 7.9 RXi: RXI-109 Revenue ($m), AGR (%), 2014-2025
Figure 7.10 Silenseed: siG12D-LODER Revenue ($m), AGR (%), 2014-2025
Figure 7.11 Roche: SPC3649 Revenue ($m), AGR (%), 2014-2025
Figure 7.12 Sylentis: SYL040012 Revenue ($m), AGR (%), 2014-2025
Figure 8.1 RNAi Therapies Market: Strengths and Weaknesses, 2015-2025
Figure 8.2 RNAi Therapies Market: Opportunities and Threats, 2015-2025

Companies Listed
Acuity Pharmaceuticals (now OPKO Health)
Advirna
Aegera Therapeutics
Agilent Technologies
Alcon (subsidiary of Novartis)
Alexion
Allele Biotechnology
Allergan
Almirall
Alnylam
Altogen Labs
AmpliPhi Biosciences
Antisense Therapeutics
AptaBio
Aptose Biosciences
Arcturus Therapeutics
ArmaGen Technologies
Arrowhead Research
Ascletis Pharmaceuticals
AstraZeneca
Atugen AG (acquired by Silence Therapeutics)
Avecia OligoMedicines
Bayer
Benitec Biopharma
Biocon
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Biomics Biotechnology
Bionexus
BioNTech
BioSpring
BioSpring GmbH
Bio-Synthesis
Blueberry Therapeutics
Bristol-Myers Squibb
Calando Pharmaceuticals (subsidiary of Arrowhead)
Celsion
CRISPR Therapeutics
Cubist Pharmaceuticals (acquired by Merck)
CureVac
Dainippon Sumitomo
Dendreon
Dharmacon RNAi Technologies (part of GE Healthcare)
Dicerna
DuPont Pharmaceuticals
Eli Lilly
Entelos, Inc
Enzo Therapeutics
Enzon Pharmaceuticals
Ethicor
Ethris
Eurofins MWG-Biotech
Eurogentec
Express Scripts
Eyetech Pharmaceuticals
EZBiolab
GE Healthcare
Gene Link
Gene Signal
GeneCare Research Institute
GeneDesign
Genzyme (part of Sanofi)
Gilead Sciences
Girindus America (part of Solvay Group)
Gradalis Incorporated
Grifols
GSK
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation (merged into Silence Therapeutics)
Isarna Therapeutics
Isis Pharmaceuticals
Kalypsys
Kunshan RiboQuark Pharmaceutical Technology (RiboQuark)
Kyowa Hakko Kirin
Life Technologies
Life Technologies (part of Thermo Fisher Scientific)
Marina Biotech
MedImmune (subsidiary of AstraZeneca)
Medtronic
Merck and Co. (Merck)
Mirna Therapeutics
Moderna Therapeutics
Monsanto
Nitto Denko
Novartis
NovaRx
Noxxon Pharma
Oligoengine (division of Halo-Bio RNAi Therapeutics)
Omnia Biologics
OncoGenex
OnCore Biopharma (merged into Tekmira)
Ophthotech
OPKO Health
Otsuka
Pfizer
PharmaMar (subsidiary of Zeltia)
Pharmasset (part of Gilead Sciences)
PhaseRx
ProNAi Therapeutics
Protiva Biotherapeutics
Qiagen
Quark Pharmaceuticals
Regeneron
Regulus Therapeutics
Ribomic
Ribopharma AG (now part of Alnylam)
RiboTask
Roche
Roche Innovation Center Copenhagen (part of Roche)
RXi Pharmaceuticals
SABiosciences (part of Qiagen)
Samyang Corporation
Sanofi
Santaris Pharma (acquired by Roche)
Santen
Sarepta Therapeutics
Sigma-Aldrich
Silence Therapeutics
Silenseed
Sirna Therapeutics (assets acquired by Alnylam)
Sirnaomics
Solvay Group
SomaGenics
Suzhou Ribo Life Science
Sylentis (subsidiary of Zeltia)
Synteract Inc.
Tacere Therapeutics (acquired by Benitec)
Takeda
Tekmira
The Medicines Company (MDCO)
Thermo Fisher Scientific
Traversa Therapeutics
UniQure
Zeltia Group

Other Organisations Mentioned in this Report
American Cancer Society (ACS)
American Society of Clinical Oncology (ASCO)
American Society of Gene and Cellular Therapy (ASGCT)
Brazilian Industrial Biotech Association
Brigham Young University
Carnegie Institution for Science
Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia)
European Medicines Agency (EMA)
European Patent Office (EPO)
Georgetown University
Hannover Medical School
Kunshan RNAi Institute
Mary Crowley Cancer Research Centre
Max Planck Institute
MD Anderson Cancer Center
Ministry of Science and Technology (India)
National Institute for Health and Care Excellence (NICE) (UK)
National Institutes of Health (NIH) (US)
Ohio State University (OSU)
Pachyonychia Congenita Project
United States Food and Drug Administration (FDA)
University of Bayreuth
University of Calgary
University of Helsinki
University of Massachusetts Medical School
University of Oxford
University of Pittsburgh
US Department of Defense
Wellcome Trust
World Health Organization (WHO)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Ribonucleic Acid Interference (RNAi) Technology Market: By Application (Research and Development, Therapeutics, Drug Discovery, Agriculture), By Tools (Design/Software, Delivery Based, Monitoring, Libraries) & By Region-Forecast (2016-2021)

Ribonucleic Acid Interference (RNAi) Technology Market: By Application (Research and Development, Therapeutics, Drug Discovery, Agriculture), By Tools (Design/Software, Delivery Based, Monitoring, Libraries) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • October 2016
  • by Industry ARC

RNAi (Ribonucleic Acid Interference) a system in live cells to keep a check on the active genes is the next promising technology in the field of biotechnology. The major classes of RNAi are micro RNA and ...

Global RNAi Technology Market - Growth, Trends And Forecasts 2014 - 2019

Global RNAi Technology Market - Growth, Trends And Forecasts 2014 - 2019

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The global market for RNAi technology is estimated to be USD 8.7 billion in 2014 and is expected to reach USD21.9 billion by 2019, growing at a CAGR of 20.19% RNA interference (RNAi) is a natural process ...

Global RNAi Technologies Market Analysis & Trends - Industry Forecast to 2025

Global RNAi Technologies Market Analysis & Trends - Industry Forecast to 2025

  • $ 4200
  • Industry report
  • September 2016
  • by Accuray Research LLP

Global RNAi Technologies Market Analysis & Trends - Industry Forecast to 2025 The Global RNAi Technologies Market is poised to grow at a CAGR of around 20.4% over the next decade to reach approximately ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.